Autolus Therapeutics (6A3A) Stock Overview
A clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
6A3A Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Autolus Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.36 |
| 52 Week High | US$2.26 |
| 52 Week Low | US$1.04 |
| Beta | 2.02 |
| 1 Month Change | -13.38% |
| 3 Month Change | 22.52% |
| 1 Year Change | -30.26% |
| 3 Year Change | -37.04% |
| 5 Year Change | -74.81% |
| Change since IPO | -93.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6A3A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 5.4% | 0.8% | -1.7% |
| 1Y | -30.3% | -7.6% | -0.6% |
Return vs Industry: 6A3A underperformed the German Biotechs industry which returned -7.6% over the past year.
Return vs Market: 6A3A underperformed the German Market which returned -0.6% over the past year.
Price Volatility
| 6A3A volatility | |
|---|---|
| 6A3A Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in DE Market | 13.4% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 6A3A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6A3A's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 753 | Chris Itin | www.autolus.com |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia.
Autolus Therapeutics plc Fundamentals Summary
| 6A3A fundamental statistics | |
|---|---|
| Market cap | €376.26m |
| Earnings (TTM) | -€253.74m |
| Revenue (TTM) | €81.33m |
Is 6A3A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6A3A income statement (TTM) | |
|---|---|
| Revenue | US$92.62m |
| Cost of Revenue | US$208.48m |
| Gross Profit | -US$115.85m |
| Other Expenses | US$173.11m |
| Earnings | -US$288.96m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.09 |
| Gross Margin | -125.08% |
| Net Profit Margin | -311.98% |
| Debt/Equity Ratio | 265.7% |
How did 6A3A perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/29 10:36 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Autolus Therapeutics plc is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Shin | Deutsche Bank |
| Rajan Sharma | Goldman Sachs |
| Emily Bodnar | H.C. Wainwright & Co. |